Abstract: A liquid crystal display device includes a first substrate and a second substrate; a liquid crystal layer disposed between the first and second substrates; gate wirings disposed on the second substrate; source wirings disposed to intersects with the gate wirings; light shielding films provided to cover the source wirings; a first insulating film provided to cover the gate wirings, the source wirings and the light shielding films; signal electrodes provided on the first insulating film, each of which is located in a region surrounded with the gate wirings and the source wirings; a common electrode provided on the first insulating film so as not to be overlapped on the signal electrodes; and shield electrode disposed between each of the signal electrodes and each of the source wirings, the respective shield electrodes being overlapped on the light shielding films.

Abstract: The invention provides a method of culturing a corneal endothelial cell by use of a culture medium containing an ascorbic acid derivative and the like.

Abstract: Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.

Abstract: An image processing apparatus is configured as follows. Namely, an image processing apparatus is provided with an imaging device in which a plurality of types of imaging elements having different spectral sensitivities are aligned on a single plane and which obtains a color imaging signal, first edge direction judging unit which judges a direction along which an edge is produced in the color imaging signal based on pixel values of the respective imaging elements, a high-color difference region judging unit which judges a region where the pixel values have a high-color difference, second edge direction judging unit which further judges a direction of the edge, direction dependence smoothing unit which smoothes the pixel values of the respective imaging elements by interpolating them along the direction, and omnidirectional smoothing unit which smoothes the pixel values of the respective imaging elements in all directions based on pixel values of peripheral pixels.

Abstract: A resource management apparatus includes a resource management part to manage an amount of resources used and an amount of virtual resources of each of a plurality of processing units, a selection and control part to select a processing unit having a smallest sum of the amount of resources used and the amount of virtual resources in response to an external process request, and to increase the amount of resources used by the selected processing unit and to decrease the amount of resources used by a processing unit corresponding to an external process release request in response to the process release request, a virtual resource control part to increase the amount of virtual resources of the processing unit corresponding to the process release request in response to the process release request, and a request sending part to send the external process request or process release request to the selected or corresponding processing unit.

Abstract: A packet processing device that achieves stable operation by alleviating the workload of packet processing. A packet buffer checks a packet length flag and a processing time flag to observe the device's operating condition for a first connection. When neither of the two flags are on, the packet buffer keeps buffering first packets on the first connection. When either or both flags are on, the packet buffer changes focus to a second connection and begins buffering second packets on the second connection. A packet length monitor turns on the packet length flag if a new cumulative packet length is greater than a packet length threshold. A processing time monitor turns on the processing time flag if a new cumulative processing time estimate is greater than a predetermined processing time threshold.

Abstract: An image processing apparatus is configured as follows. Namely, an image processing apparatus is provided with an imaging device in which a plurality of types of imaging elements having different spectral sensitivities are aligned on a single plane and which obtains a color imaging signal, first edge direction judging unit which judges a direction along which an edge is produced in the color imaging signal based on pixel values of the respective imaging elements, a high-color difference region judging unit which judges a region where the pixel values have a high-color difference, second edge direction judging unit which further judges a direction of the edge, direction dependence smoothing unit which smoothes the pixel values of the respective imaging elements by interpolating them along the direction, and omnidirectional smoothing unit which smoothes the pixel values of the respective imaging elements in all directions based on pixel values of peripheral pixels.

Abstract: Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.

Abstract: It is intended to provide a method of efficiently and stably preparing a cell having a bone tissue formation ability by a simple operation. Further, it is intended to provide a method of preparing a composition for bone tissue formation with high safety and an excellent therapeutic effect by a simple operation. The cell for bone tissue formation is obtained by (1) culturing bone marrow after isolating it from a living body, diluting it at a predetermined dilution ratio and inoculating it to a culture vessel, (2) culturing the remaining adhesive cells after removing floating components, (3) inducing differentiation of proliferated cells to bone cells and (4) recovering the cells. The thus obtained cells, a thrombin solution, platelet-rich plasma and air are mixed at a predetermined mixing ratio (based on volume) in the presence of calcium ions and the mixture is gelled, whereby a gelled composition is obtained.

Abstract: Novel proteins and polypeptides binding to osteoclastogenesis inhibitory factor (OCIF) (OCIF-binding molecules, OBMs) and nucleic acids encoding these proteins and polypeptides are provided. Processes for producing these proteins, polypeptides, and nucleic acid molecules by genetic engineering are provided. Medicinal compounds are provided which comprise proteins and nucleic acids according to the invention, as well as proteins which bind to OBM, including anti-OBM antibodies. These compounds may be used for the treatment of bone disease.

Abstract: A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Abstract: The present invention relates to a novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. In addition, screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance are disclosed. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising the antibody are also disclosed.

Abstract: A novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. Screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising this antibody.

Abstract: A resource management apparatus includes a resource management part to manage an amount of resources used and an amount of virtual resources of each of a plurality of processing units, a selection and control part to select a processing unit having a smallest sum of the amount of resources used and the amount of virtual resources in response to an external process request, and to increase the amount of resources used by the selected processing unit and to decrease the amount of resources used by a processing unit corresponding to an external process release request in response to the process release request, a virtual resource control part to increase the amount of virtual resources of the processing unit corresponding to the process release request in response to the process release request, and a request sending part to send the external process request or process release request to the selected or corresponding processing unit.

Abstract: A packet processing device that achieves stable operation by alleviating the workload of packet processing. A packet buffer checks a packet length flag and a processing time flag to observe the device's operating condition for a first connection. When neither of the two flags are on, the packet buffer keeps buffering first packets on the first connection. When either or both flags are on, the packet buffer changes focus to a second connection and begins buffering second packets on the second connection. A packet length monitor turns on the packet length flag if a new cumulative packet length is greater than a packet length threshold. A processing time monitor turns on the processing time flag if a new cumulative processing time estimate is greater than a predetermined processing time threshold.

Abstract: A protein which inhibits osteoclast differentiation and/or maturation and a method of production of the protein. The protein is produced by human embryonic lung fibroblasts and has molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis, respectively. The protein can be isolated and purified from culture medium of the said fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity to the protein or a method for determination of the protein concentration using the antibodies.

Abstract: A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.

Abstract: The present invention relates to a novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. In addition, screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance are disclosed. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising the antibody are also disclosed.

Abstract: A novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein. Screening methods for a substance for controlling expression of said protein using said protein and the DNA, a substance which inhibits or modulates the biological activity of said protein, or a receptor which transmits the action of said protein through binding to said protein, the substance obtained by the screening methods, and a pharmaceutical composition which contains this substance. An antibody for said protein, a process for preparing the same, a measuring method of said protein using the antibody, and a medicine comprising this antibody.

Abstract: A protein which inhibits osteoclast differentiation and/or maturation and a method for producing the protein. The protein is produced by human embryonic lung fibroblasts and has a molecular weight of about 60 kD and about 120 kD under non-reducing conditions and about 60 kD under reducing conditions on SDS-polyacrylamide gel electrophoresis. The protein can be isolated and purified from the culture medium of fibroblasts. Furthermore, the protein can be produced by gene engineering. The present invention includes cDNA for producing the protein by gene engineering, antibodies having specific affinity for the protein or a method for determining protein concentration using these antibodies.